A review of gliptins in 2011

Bibliography

• Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008;68:2131-62
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-18
   PubMed Web of Science ®Google Scholar
• Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97
   PubMed Web of Science ®Google Scholar
• Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112
   PubMed Web of Science ®Google Scholar
• Banerjee M, Younis N, Soran H. Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother 2009;10:2745-57
   PubMed Web of Science ®Google Scholar
• Ahren B, Schweizer A, Dejager S, Mechanisms of action of the DPP-4 inhibitor vildagliptin in man. Diabetes Obes Metab 2011;13:775-83
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Campbell RK. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:1515-25
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009;26:488-99
   PubMed Web of Science ®Google Scholar
• Kania DS, Gonzalvo JD, Weber ZA. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33:1005-22
   PubMed Web of Science ®Google Scholar
• Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
   PubMed Web of Science ®Google Scholar
• Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011;71:611-24
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs 2011;20:723-32
   PubMed Web of Science ®Google Scholar
• Gupta R, Walunj SS, Tokala RK, Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 2009;10:71-87
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
   PubMed Web of Science ®Google Scholar
• Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011;13:193-203
   PubMed Web of Science ®Google Scholar
• Esposito K, Cozzolino D, Bellastella G, Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011;13:594-603
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57
   PubMed Web of Science ®Google Scholar
• Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-40
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. 2010;12:648-58
   Google Scholar
• Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol 2011;7:1065-82
   PubMed Web of Science ®Google Scholar
• Kirby M, Yu DM, O'Connor S, Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2010;118:31-41
   Web of Science ®Google Scholar
• Monami M, Cremasco F, Lamanna C, Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011;27:362-72
   PubMed Web of Science ®Google Scholar
• Chapell R, Gould AL, Alexander CM. Baseline differences in A1c explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab 2009;11:1009-16
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Stonehouse AH, Han J, Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010;27:309-17
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
   PubMed Web of Science ®Google Scholar
• Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512
   PubMed Web of Science ®Google Scholar
• Ahren B, Landin-Olsson M, Jansson PA, Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84
   PubMed Web of Science ®Google Scholar
• Vella A, Bock G, Giesler PD, Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475-80
   PubMed Web of Science ®Google Scholar
• Pratley RE, Schweizer A, Rosenstock J, Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-8
   PubMed Web of Science ®Google Scholar
• Holst JJ, Christensen M, Lund A, Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011;13(Suppl 1):89-94
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-84
   PubMed Web of Science ®Google Scholar
• Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl 2007;154:19-28
   PubMedGoogle Scholar
• Barnett A, Allsworth J, Jameson K, A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 2007;23:1493-507
   PubMed Web of Science ®Google Scholar
• Waters SB, Topp BG, Siler SQ, Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol 2009;3:68-82
   PubMedGoogle Scholar
• Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010;6:541-8
   PubMedGoogle Scholar
• Rizzo M, Rizvi AA, Spinas GA, Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 2009;18:1495-503
   PubMed Web of Science ®Google Scholar
• Marney A, Kunchakarra S, Byrne L, Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010;56:728-33
   PubMed Web of Science ®Google Scholar
• Mistry GC, Maes AL, Lasseter KC, Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592-8
   PubMed Web of Science ®Google Scholar
• Jackson EK. Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome. Hypertension 2010;56:581-3
   PubMedGoogle Scholar
• Ogawa S, Ishiki M, Nako K, Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med 2011;223:133-5
   PubMedGoogle Scholar
• Tanaka T, Nangaku M, Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr Opin Nephrol Hypertens 2011;20:476-81
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Deacon CF, Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:366-73
   PubMed Web of Science ®Google Scholar
• Matikainen N, Manttari S, Schweizer A, Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57
   PubMed Web of Science ®Google Scholar
• Boschmann M, Engeli S, Dobberstein K, Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009;94:846-52
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA, Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-49
   PubMed Web of Science ®Google Scholar
• Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011;58:69-73
   PubMed Web of Science ®Google Scholar
• Fadini GP, Boscaro E, Albiero M, The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607-9
   PubMed Web of Science ®Google Scholar
• Van Poppel PC, Netea MG, Smits P, Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011;34:2072-7
   PubMed Web of Science ®Google Scholar
• Shah Z, Pineda C, Kampfrath T, Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul pharmacol 2011;55:2-9
   PubMedGoogle Scholar
• Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascul Pharmacol 2011;55:10-16
   PubMed Web of Science ®Google Scholar
• van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab 2011; published on line 2011/07/15; doi: 10.1111/j.1463-1326.2011.01473.x.
   PubMedGoogle Scholar
• Wajchenberg BL. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010;654:515-35
   Google Scholar
• Xu L, Man CD, Charbonnel B, Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008;10:1212-20
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Qi Y, Opsteen C, Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010;12:909-15
   PubMed Web of Science ®Google Scholar
• Foley JE, Bunck MC, Moller-Goede DL, Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011;54:1985-91
   PubMedGoogle Scholar
• Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011;33:511-27
   PubMed Web of Science ®Google Scholar
• Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011;34:369-74
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Engel SS, Round E, Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011;7:49-57
   PubMedGoogle Scholar
• Engel SS, Williams-Herman DE, Golm GT, Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Butler PC, Matveyenko AV, Dry S, Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6
   PubMed Web of Science ®Google Scholar
• Brown NJ, Byiers S, Carr D, Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009;54:516-23
   PubMed Web of Science ®Google Scholar
• Desai S, Brinker A, Swann J, Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med 2010;170:1169-71
   PubMed Web of Science ®Google Scholar
• Byrd JS, Minor DS, Elsayed R, DPP-4 inhibitors and angioedema: a cause for concern? Ann Allergy Asthma Immunol 2011;106:436-8
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Exenatide once weekly in type 2 diabetes. Lancet 2008;372:1197-8
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
   PubMed Web of Science ®Google Scholar
• Seck TL, Engel SS, Williams-Herman DE, Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Res Clin Pract 2011;93:e15-17
   Google Scholar
• Nicolucci A, Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008;79:184-91
   PubMedGoogle Scholar
• Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009;29:55S-67S
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2011; published on line; doi: In press
   Google Scholar
• Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-12
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76
   PubMed Web of Science ®Google Scholar
• Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs 2011;71:349-61
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Piya MK, Barnett AH. Drug evaluation: vildagliptin-metformin single-tablet combination. Adv Ther 2009;26:138-54
   PubMed Web of Science ®Google Scholar
• Halimi S, Schweizer A, Minic B, Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008;4:481-92
   PubMedGoogle Scholar
• Saxagliptin/metformin (Kombiglyze XR) for type 2 diabetes. Med Lett Drugs Ther 2011;53:21-2
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Saxagliptin and metformin combination therapy. Expert Rev Endocrinol Metab 2011; In press
   Google Scholar
• Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008;4:383-94
   PubMedGoogle Scholar
• De Fronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 2008;4:1221-7
   PubMedGoogle Scholar
• Scheen AJ, Tan MH, Betteridge DJ, Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med 2009;26:1033-9
   PubMed Web of Science ®Google Scholar
• Hermansen K, Kipnes M, Luo E, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
   PubMed Web of Science ®Google Scholar
• Owens DR, Swallow R, Dugi KA, Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study(1). Diabet Med 2011;28:1352-61
   PubMed Web of Science ®Google Scholar
• Bosi E, Ellis GC, Wilson CA, Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011;13:1088-96
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrecht D, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Yi B, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4
   PubMed Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65
   PubMed Web of Science ®Google Scholar
• He Y, Flannery B, Wang Y, The influence of renal impairment on pharmacokinetics of vildagliptin. Clin Pharmacol Ther 2007;81:S113; PIII-86
   Google Scholar
• Karim A, Fleck P, Hetman L, Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes 2008;57(Suppl 1):A160; 538-P
   Google Scholar
• Graefe-Mody U, Friedrich C, Port A, Effect of Renal Impairment on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin. Diabetes Obes Metab 2011;13:939-46
   PubMed Web of Science ®Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-43
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Shao Q, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54
   PubMed Web of Science ®Google Scholar
• Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract 2010;90:182-90
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin for the treatment of type 2 diabetes (Pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol 2011;7:1561-76
   PubMed Web of Science ®Google Scholar
• Migoya EM, Stevens CH, Bergman AJ, Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16:e165-70
   PubMedGoogle Scholar
• He YL, Sabo R, Campestrini J, The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007;63:677-86
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Dorsey D, Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment. J Clin Pharmacol 2007;47:abstract 107
   Google Scholar
• Graefe-Mody U, Rose P, Ring A, The novel DPP-4 inhibitor linagliptin can be administered to patients with various degrees of hepatic impairment without dose adjustment. J Diabetes 2011;3(Suppl 1):220
   Google Scholar
• Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap) 2011;39:7-21
   PubMedGoogle Scholar
• Schweizer A, Dejager S, Foley JE, Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >/ = 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011;13:55-64
   PubMed Web of Science ®Google Scholar
• Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010;8:405-18
   PubMed Web of Science ®Google Scholar
• Barzilai N, Guo H, Mahoney EM, Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Bhattacharyya OK, Estey EA, Cheng AY. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009;55:39-43
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Barnett AH, Betteridge DJ, Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-69
   PubMed Web of Science ®Google Scholar
• Excellence. NIfHaC. The Management of Type 2 Diabetes: 2010 NICE Guidelines [Internet]. London, U.K., National Institute for Health and Clinical Excellence, 2010. Available from: http:/wwwniceorguknicemedia/live/12165/44320/44320pdf [Last accessed 15 November 2011]
   Google Scholar
• Pozzilli P, Leslie RD, Chan J, The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-44
   PubMed Web of Science ®Google Scholar
• Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors (2003). J Am Pharm Assoc 2009;49(Suppl 1):S16-29
   Google Scholar
• Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol 2011;203:53-74
   Google Scholar
• Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-16
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors are favourable to GLP-1 receptor agonists: yes. Eur J Intern Med 2011; In press
   PubMedGoogle Scholar
• Anagnostis P, Athyros VG, Adamidou F, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-12
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
   PubMed Web of Science ®Google Scholar
• White WB, Gorelick PB, Fleck P, Cardiovascular events in patients receiving alogliptin: a pooled analysis of randomized clinical trials. Diabetes 2010;59(Suppl):391-PP
   Google Scholar
• Johansen O-E, Neubacher D, Von Eynatten M, Cardiovascular Risk with Linagliptin in Patients with Type 2 Diabetes: A Pre-Specified, Prospective, and Adjudicated Meta-Analysis from a Large Phase III Program. Late Breaking Poster presented at the 71st Annual Meeting of the American Diabetes Association; 24 – 28 June 2011; San Diego, CA
   Google Scholar
• Seck T, Nauck M, Sheng D, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-76
   PubMed Web of Science ®Google Scholar
• Matthews DR, Dejager S, Ahren B, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-9
   PubMed Web of Science ®Google Scholar
• Henry RR, Smith SR, Schwartz SL, Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:850-8
   PubMed Web of Science ®Google Scholar
• Vardarli I, Nauck MA, Kothe LD, Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as “isoglycemic” intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:945-54
   PubMedGoogle Scholar
• He Y, Sabo R, Campestrini J, The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007;63:677-86
   PubMed Web of Science ®Google Scholar